BOC Sciences provides personalized antibody conjugation services to support research and development in the field of antibody drugs. As a leading service provider of bioconjugation, our antibody bioconjugation services include antibody conjugated PEG, biotin, fluorescence dye, enzyme and oligonucleotide, which have been proven to improve the function and performance of antibody drugs, as well as to use for imaging and detection. Furthermore, antibody-drug conjugation services are provided to support the forefront of antibody-drug conjugates (ADCs) development.


Antibody-based drugs have become an important class of biological drugs. The monoclonal antibody (mAb) and its derivatives, such as antibody-drug conjugates (ADCs), bispecific antibodies, have been widely used in the effective treatment of human diseases, particularly in the fields of immunology and oncology. In antibody-based therapy, various antibody derivatization approaches are used to improve the performance of antibodies or to test antibody drugs. For instance, the conjugation of PEG to antibodies can enhance the solubility of antibodies, reduce immunogenicity, and increase the circulating half-lives of antibodies. In addition, exploiting the character of antibodies binding specifically to antigens, antibodies labeled with chromogenic agents, such as fluorophore, enzyme, biotin, etc., provides a tool for the localization, characterization and quantification of antigens in biological tissues. With increased understanding of immunobiology and the continued development of molecular biology methods, it is believed that the possibilities of antibody-based therapeutics are bounded only by the scope of human ingenuity.


Antibody conjugates have been widely used in antigen detection and disease diagnoses, such as proteins identification and cancerous tumors diagnosis, involving chromogenic immunohistochemistry (CIH) and immunofluorescence technologies. Improvements in the methods for antibody conjugate synthesis promote the development of antibody-drug conjugates (ADCs), which sensitively distinguish healthy tissues from diseased tissues for targeting cancer while minimizing healthy tissue exposure. As a new class of biomolecules, antibody-oligonucleotide conjugates (AOCs) have become important biotechnology for imaging, detection, and therapeutics such as targeted siRNA and antisense delivery.

Our Advantages

  • Profound knowledge and extensive experience in antibody conjugation
  • Comprehensive antibody conjugation service and leading antibody technology
  • People and suites that specialize in ADC development, manufacturing and testing
  • High levels of antibody recovery so to save your precious reagents
  • Full technical support
  • Reliable and reproducible result
  • Detailed report and data analysis, including results and discussion